Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1057 articles with Regeneron Pharmaceuticals, Inc.
During the past two years, fundraising and investment in biotechnology have reached record levels.
9/20/2021Three weeks after snagging approval in the UK, the U.S. FDA approved Samsung Bioepis and Biogen’s biosimilar drug. Byooviz is the first Lucentis copycat biologic to hit the market.
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
Positive Phase 3 results for Sanofi and Regeneron Pharmaceuticals, Inc.’s Libtayo® combination treatment were presented during a late-breaking session at the European Society for Medical Oncology Virtual Congress 2021.
The top three clusters from last year's list - Greater Boston, San Francisco Bay Area and San Diego - all stood their ground and maintained their rankings from the previous year.
Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail
New agreement for 1.4 million doses of REGEN-COV, brings total purchased by the U.S. government to nearly 3 million doses
Recently launched biotech company Immunai is pairing artificial intelligence and machine learning in an attempt to tailor treatments and improve patient outcomes.
9/7/2021Is your job burning you out? According to BioSpace's recent research, approximately 70% of biotech professionals feel burned out. Is it time to look for a new job? The good news is that biotech companies keep adding jobs and the market is hot! Check out these hot companies that are looking for c...
The analysis showed tezepelumab achieved an 86% reduction in the annualized asthma exacerbation rate with patients having nasal polyps, and 52% in patients not having nasal polyps.
On June 26, Intellia announced the first-ever clinical data supporting the safety and efficacy of in vivo CRISPR genome editing in human patients.
Regeneron and Sanofi broke ground with the 2017 approval of the first biologic drug for atopic dermatitis, the most common form of eczema driven by allergic reactions.
Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
A pivotal Phase 3 trial evaluating Dupixent® for the treatment of children aged 6 months to 5 years with moderate-to-severe atopic dermatitis, a chronic type 2 inflammatory disease, met its primary and all secondary endpoints.
Approximately 14,000 American women are expected to be diagnosed with invasive cervical cancer in 2021, and more than 4,000 are expected to succumb to the disease.
Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration
Regeneron Pharmaceuticals, Inc. announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA® Injection in patients with wet age-related macular degeneration.
Regeneron Pharmaceuticals, Inc. announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency has granted Conditional Marketing Authorization for the casirivimab and imdevimab antibody cocktail, known as REGEN-COV™ in the U.S. and Ronapreve® in the UK and other countries, to prevent and treat acute COVID-19 infection.
The amended EUA is aimed at patients who have undergone solid organ transplants or those diagnosed with conditions that have an “equivalent level of immunocompromised.”
Regeneron Pharmaceuticals, Inc. announced financial results for the second quarter of 2021 and provided a business update.
Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals, Inc. and Sanofi announced the Phase 3 trial of PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival primary endpoint in patients with advanced non-small cell lung cancer.
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
The Phase 3 trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival primary endpoint in patients with advanced non-small cell lung cancer.
The Phase III trial shows that PD-1 inhibitor Libtayo and platinum-doublet chemotherapy significantly improved OS compared with chemotherapy alone with locally advanced NSCLC.
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to prevent COVID-19 infection among household contacts of SARS-CoV-2 infected individuals.